STAT+: ‘Patchy efforts’ by major insulin makers mean access lags in many poor countries
The three companies that dominate the global market for insulin have launched various programs to…
Category: Pharma
Opinion: The new law that could stealthily transform biomedical innovation
Buried deep within the Inflation Reduction Act’s drug-price negotiation provisions is language that could open…
STAT+: Medicare tasks a senior adviser with staffing its new drug pricing division
WASHINGTON — Medicare has tasked a senior adviser at the agency with assembling a small…
STAT+: Pharmalittle: Nobel awarded for novel chemistry used in drug development; Biden will nominate surgeon general for WHO post
Good morning, Pharmalitte students. I’m Allison DeAngelis, substituting for Ed today. It’s a rainy day…
STAT+: Pharmalittle: U.S. Supreme Court asks solicitor general for views on ‘skinny label’ case; Express Scripts and Kroger are mired in dispute
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Opinion: How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process
The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday…
STAT+: Pharmalittle: Price of new ALS drug prompts criticism; many drug price hikes exceeded U.S. inflation rate
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Many trials to confirm benefits of drugs granted accelerated approvals are running late
Amid heightened debate over a regulatory program for speeding the approval of some medicines, a…
STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Medicare plans sizable infrastructure for negotiating drug prices; Alzheimer’s data also boost Roche and Lilly
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Medicare lays out the bureaucracy it will need to negotiate drug prices
WASHINGTON — New documents obtained by STAT outline how Medicare is planning to build out…
STAT+: Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Lilly is accused by the federal government of discriminating against older sales reps
In an unusual move, the U.S. Equal Employment Opportunity Commission has filed a lawsuit accusing…
STAT+: Pharmalittle: Democrats concede on passing ‘clean’ FDA funding bill; Biogen whistleblower nets $250 million
Good morning, one and all. Damian here, filling in for Ed Silverman once more. Here…
STAT+: Pharmalittle: GSK picks its first female CFO; Pfizer advances Omicron booster for kids
Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the outset of…
Opinion: FDA: Ignore a pharma company’s deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug
In an effort to sway the Food and Drug Administration not to withdraw accelerated approval…
Opinion: Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era
Here’s a scenario anyone who has done clinical research will recognize: A 32-year-old woman participating…
STAT+: Some European regulators are starting to take steps to ensure clinical trial results are reported
Regulators in half a dozen European countries are now taking steps to enforce requirements that…
STAT+: Pharmalittle: U.S. drug net prices fell nearly 8% in the second quarter; FDA panel favors fecal-based therapy for bacterial infections
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: Solicitor general recommends Supreme Court shouldn’t review an Amgen patent case
In a setback to Amgen, the U.S. solicitor general recommended that the Supreme Court not…
STAT+: Inflation caused another big drop in net drug prices, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
Opinion: Market share isn’t the only metric for biosimilars’ success
Market share is often held up as the most relevant metric for the success of…
STAT+: Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority
Hello, everyone, and how are you today? A dank cloudy cover greeted us this morning,…
STAT+: Pharmalittle: FDA scolds Catalent over quality control at plant making Covid shots; Novartis will ask SCOTUS to protect a key patent
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Catalent is scolded by FDA for quality control issues at a plant that helps make Covid-19 vaccines
Catalent, one of the largest contract manufacturers in the pharmaceutical industry, was cited by the…
STAT+: Pharmalittle: Haleon argues it’s not liable for any Zantac claims; FDA steps up surprise inspections in India
Top of the morning to you, and a fine one it is. Crystal clear blue…
House Democrat presses bill to encourage more diversity in clinical trials run by NIH
Rep. Robin Kelly admits that the word “diversity” has scared some of her Republican colleagues…
STAT+: Pfizer accused of running a fellowship program that discriminates on racial grounds
In a move reflecting simmering controversy over diversity and equity, Pfizer has been accused of…
STAT+: Pharmalittle: Advances in treating the sickest Covid patients have stalled; Moderna aids WHO effort to develop mRNA coronavirus shots
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug
In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several…
STAT+: Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Swiss authorities raid Novartis offices seeking info on patents used to block rivals
The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use…
STAT+: Pharmalittle: Pharma pursues the ‘dream’ of online prescribing; EC chief under fire over Pfizer vaccine contract
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: Biden picks biotech exec to lead new biomedical research agency; FDA to hold meeting for OTC birth control pill
Hello, everyone, and how are you today? The skies over the Pharmalot campus remain gloomy…
STAT+: Pharmalittle: FDA approves new type of psoriasis drug; U.S. starts late-stage trial to test an antiviral against monkeypox
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: USDA starts cracking down on companies that ship animals without timely inspections
Earlier this year, a leading animal rights group asked U.S. authorities to investigate medical research…
STAT+: J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review
In an unusual turn of events, an appeals panel ruled that the U.K.’s cost effectiveness…
STAT+: Pharmalittle: FDA approves a new wrinkle drug; running remote clinical trials can save pharma money
And so, another working week will soon draw to a close. Not a moment too…
STAT+: What disclosure? Clinical trials run in Canada fail to take basic steps toward transparency
Amid ongoing controversy over clinical trial transparency, a new analysis found that just 3% of…
STAT+: Even before Covid-19, remote trials saved money. Will pharma now rely on them more than ever?
Running clinical trials remotely or virtually can provide substantial financial savings for pharmaceutical companies, according…
STAT+: Pharmalittle: FDA advisers recommend approval of controversial ALS drug; judge rules against coverage of HIV prevention drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Pharmalittle: FDA holds rare second meeting over an ALS drug; U.S. to expand distribution for monkeypox vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharma donations to patient charities may violate the ‘spirit’ of anti-kickback laws
There is a federal law that prohibits drug companies from directly covering out-of-pocket spending by…
STAT+: Bayer agrees to $40 million settlement over kickbacks and downplaying drug safety risks
After nearly two decades of litigation, Bayer agreed to pay $40 million to settle a…
STAT+: Pharmalittle: Illumina deal for Grail is blocked after EU veto; CVS buys Signify to expand into house calls
Good morning, everyone, and nice to see you again after a much-welcomed and extended break…
STAT+: Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Good morning, everyone. I’m Jason Mast, the last of the understudies filling in while Ed…
STAT+: Pharmalittle: FDA authorizes new Covid boosters; a setback for federal efforts to regulate stem cell clinics
Good morning. This is Jonathan with you once more. We’re now close enough to the…
STAT+: Pharmalittle: An emerging star in biotech investment; U.S. government expected to stop paying for Covid shots next year
Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m…
STAT+: In a new lawsuit, pharma-backed patient groups fight federal rule around copay coupons
Three patient advocacy groups are suing the Biden administration to challenge a federal regulation they…